Journal of Ophthalmic Inflammation and Infection

Table 12 Flare value measured by LFCM by treatment and visit (ITT)

From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients

		Day 1	Day 3	Day 7	Day 14
Nepafenac group	Mean	20.6	20.6	13.4	11.4
	Std	24.6	40.9	12.2	9.1
	N	101	103	103	103
	Min	0.5	0.3	0.4	0.3
	Max	153.2	396.7	57.8	57.8
Placebo group	Mean	24.3	47.5	65.6	52.0
	Std	34.4	49.8	77.7	69.9
	N	101	104	104	104
	Min	1.8	2.5	2.5	1.5
	Max	307.6	333.9	479.7	479.7
P value		0.6201	<0.0001	<0.0001	<0.0001

Non-baseline P values are LSMeans by visit; test = repeated measure ANOVA, main effect of treatment P < 0.0001; treatment by visit interaction P < 0.0001
Min minimum, Max maximum, Std standard deviation

Back to article page